Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Neoplasm Metastasis 39Lymphoma 27Multiple Myeloma 24Colorectal Neoplasms 20Leukemia, Myeloid, Acute 18Melanoma 13Lung Neoplasms 13Prostatic Neoplasms 12Pancreatic Neoplasms 12Ovarian Neoplasms 12Breast Neoplasms 11Sarcoma 10Triple Negative Breast Neoplasms 9Lymphoma, Non-Hodgkin 9Fallopian Tube Neoplasms 9Burkitt Lymphoma 9Urinary Bladder Neoplasms 8Neuroblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Myelodysplastic Syndromes 7Lymphoma, Follicular 7Endometrial Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5

Interventions

Rituximab 6fludarabine phosphate 3Vorinostat 3Specimen Handling 3Biopsy 3sargramostim 2ibrutinib 2binimetinib 2Sunitinib 2RFB4(dsFv)-PE38 recombinant immunotoxin 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2MK 2206 2Interferon-alpha 2Ifosfamide 2Flow Cytometry 2Etoposide 2Diphenhydramine 2Cladribine 2Carboplatin 2Bendamustine Hydrochloride 2B3(Fv)-PE38KDEL recombinant immunotoxin 2Analgesia 2Acetaminophen 2venetoclax 1veliparib 1tovorafenib 1tanespimycin 1obatoclax 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Leukemia, Hairy Cell × Biopsy × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06311227 2026-05-13

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡